Purpose of the development: To improve human performance with all types of hypoxia. For the treatment of radiation sickness, Meniere's disease.

Recommended application field: Medicine.

Advantages over analogues: The drug has pronounced immunostimulating properties. The drug accelerates adaptation to a wide range of adverse effects on the body and provides a longer adaptation preservation time.

The development stage readiness: Tested experimental exploitation order

Description of the development:
()
An anti-asthenic agent for asthenic disorders of an organic and psychogenic nature. The combination in the preparation of anti-asthenic and reparative effects is used in the treatment of patients with radiation sickness. The drug has a therapeutic effect in vestibular disorders, labyrinthopathies and Meniere's disease.

corresponds technical description
Ready for implementation

Possibility of transfer abroad:
Combinated reduction to industrial level
Joint production, sale, exploitation

Photo

Country Ukraine

For additional information turn to:
E-mail: gal@uintei.kiev.ua